Skip to main content

Table 1 ACPA fine-specificities in anti-CCP2+ and anti-CCP- RA and controls

From: Presence of autoantibodies in “seronegative” rheumatoid arthritis associates with classical risk factors and high disease activity

ACPA fine-specificities Antibody frequencies (%) Antibody levels (median)a
CCP2+ CCP2− Controls p valueb CCP2+ CCP2− p valuec
Cit-Fibß60–74 80.6 9.5 0.8 < 0.0001 195.3 27.1 < 0.0001
Cit-peptide-5 75.4 8.6 1.1 < 0.0001 81.4 27.2 < 0.0001
Cit-peptide-Z1 69.3 5.1 0.5 0.0001 167.4 38.6 < 0.0001
Cit-Fibß36–52 65.6 5.0 1.4 0.003 605.0 186.4 < 0.0001
Cit-Vim60–75 63.5 2.9 1.1 0.049 641.6 321.9 0.009
CEP-1 60.9 4.4 1.1 0.003 678.2 316.1 < 0.0001
cfc1-cyc (CCP1) 59.9 3.8 1.1 0.009 514.7 166.0 < 0.0001
Cit-Fibα563–583 57.6 2.5 1.1 0.10 444.8 144.0 0.002
Cit-peptide-Z2 49.5 2.9 0.3 0.003 150.9 58.6 0.002
Cit-peptide-1 45.0 4.7 1.9 0.02 72.7 29.2 < 0.0001
Cit-Fibα621–635 42.9 4.6 1.4 0.005 384.0 123.0 < 0.0001
Cit-peptide-Bla26 39.9 4.4 1.4 0.006 80.3 48.7 0.003
Cit-Vim2–17 40.3 2.6 1.4 0.16 75.9 72.8 0.712
Cit-F4(Cit-Cit) 36.1 3.4 1.6 0.08 84.9 60.6 0.032
Cit-F4(R-Cit) 29.9 2.1 1.4 0.36 86.4 80.6 0.366
Cit-Fibα580–600 24.2 2.8 1.4 0.11 264.2 197.2 0.024
Cit-Fibα36–50 17.6 4.0 1.9 0.053 422.9 265.5 < 0.0001
Cit-C1 10.8 1.9 1.4 0.48 69.3 87.9 0.383
Cit-F4(Cit-R) 6.2 1.8 1.1 0.34 403.0 306.5 0.382
  1. aMedian antibody levels are shown for ACPA+ patients only. P values indicate differences between banti-CCP2− RA and controls or between canti-CCP2+ and anti-CCP2− RA